Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 21,33 € (+19,16 %). Medianen er 21,38 € (+19,44 %).
| Køb |
7 |
| Behold |
5 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia
Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Mere på finanzen.net
Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business
Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Mere på finanzen.net
Fortrea buys early-phase unit from Worldwide for $45 million
Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Mere på de.investing.com
Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials
Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Mere på finanzen.net
Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials
Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 610,49 mio. | 2,16 % |
| Bruttofortjeneste | 123,16 mio. | 40,18 % |
| Nettoresultat | 529,71 t | 103,91 % |
| EBITDA | 32,31 mio. | 180,88 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,69 mia. € |
Antal aktier | 94,6 mio. |
Højeste/laveste i 52 uger | 23,80 € - 7,78 € |
| Udbytte | Nej |
Beta | 1,86 |
P/E (PE Ratio) | -25,99 |
PEG (PEG Ratio) | -0,11 |
K/I (PB Ratio) | 3,52 |
P/S (PS Ratio) | 0,69 |
Virksomhedsprofil
Fortrea Holdings Inc. leverer løsninger inden for klinisk udvikling og patientadgang til life sciences-branchen. Virksomheden tilbyder klinisk forsøgsledelse i fase I-IV, klinisk farmakologi, differentierede teknologidrevne forsøgsløsninger samt services efter godkendelse. Selskabet betjener farmaceutiske virksomheder, biotekvirksomheder og producenter af medicinsk udstyr. Fortrea Holdings Inc. har hovedsæde i Durham, North Carolina.
| Navn | FORTREA HOLDINGS DL-,001 Aktie |
| CEO | Anshul Thakral |
| Hjemsted | Durham,
nc USA |
| Websted | |
| Branche | Sundhedsudstyr og -produkter |
| Børsnotering | 20.06.2023 |
| Medarbejdere | 14.000 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | FTRE |
Frankfurt | K67.F |
Düsseldorf | K67.DU |
München | K67.MU |